Health news
Dr. Vonda Wright MD, MS, brings innovative nanotechnology to Central Florida, allowing the most minimally invasive, same-day diagnosis and knee surgery without incisions, general anesthesia or post-operative narcotics….
NEW YORK – November 1, 2022 – (Newswire.com)
As a trusted name in …
Neximatic Inc Vital Sign Charting Automation
CHICAGO – November 1, 2022 – (Newswire.com)
…
Dr Olu Bamgbade
SURREY, British Columbia – November 1, 2022 – (Newswire.com)
…
The research will enable millions of people to use facemasks and protect their face from facemask-related complications
Dr Olu Bamgbade
…
NEW YORK & PITTSBURGH – November 1, 2022 – (Newswire.com)
During a single healthcare encounter, a typical consumer may have multiple, disconnected interactions with their provider and payer about the financial aspects of their visit. For example, consumers looking to pay a bill, check their deductible progress or verify their health benefit account balance might have to utilize multiple communications methods, such as phone calls, apps or provider- and insurer-affiliated web portals.
This lack of alignment leads to frustration and confusion for consumers, resulting in missed payments, overspending, administrative waste and money left on the table for consumers, who may be unaware of their available spending account funds. Not only do U.S. consumers spend 12 million hours a week on the phone with health insurers, but more than one-third of consumers have been sent to debt collections because of a billing issue between their healthcare provider and health insurer.
To address the systemic challenges consumers face when paying for healthcare, Cedar, an enterprise healthcare engagement platform that improves the end-to-end consumer financial journey, has developed the Payer Intelligence Layer. With the Payer Intelligence Layer, Cedar can now integrate data from health insurers and healthcare providers to help create a single source of information for consumers managing medical bills. A game-changer for the healthcare industry, Pittsburgh-based Highmark Inc. and Allegheny Health Network (AHN) will be the first to launch the new technology for services provided to Highmark Inc. members at AHN wholly owned providers and facilities.
“For too long, payer and provider misalignment has led to a poor experience and lack of clarity for consumers managing healthcare bills — this is a system problem, requiring a system solution,” said Seth Cohen, president of Cedar. “When each party plays a separate role, neither can fix the experience alone. But by bringing both sides together, we can create the best possible experience, reducing billing friction for consumers while delivering more efficient operations for payers and providers.”
Initially available with Cedar Pay, the company’s billing and payment solution, the Payer Intelligence Layer enables consumers to access insurance explanation of benefits, real-time deductible status and health benefit accounts in the same place where they view and resolve medical bills — using a single, intuitive interface. Unlike other patient billing solutions, Cedar ensures consumers have the most up-to-date benefits information at their fingertips by directly integrating with health insurers as well as banks, which are responsible for administering health savings accounts, flexible spending accounts and health reimbursement accounts.
“Healthcare billing can be fragmented, cumbersome and overwhelming to navigate,” said Neil Kulkarni, vice president, Customer and Clinician Experience Solutions at Highmark Health. “Consumers want clear, easy-to-understand bills for their care and a simple way to pay — with their spending account information available across all channels. As part of Highmark Health’s Living Health model designed to deliver a blended and seamless health care experience, our collaboration with Cedar will help us to meet those customer expectations,” he said.
“The financial experience in healthcare is a real pain point for most consumers, and for most care providers. The issues associated with healthcare billing can only be resolved if all major players come together and collaborate for the benefit of consumers,” said James Rohrbaugh, chief financial officer and treasurer at Allegheny Health Network. “Our work with Cedar will be important in driving real progress in this area, helping our patients and members with an intuitive experience that fosters a sense of control and understanding about their financial responsibility.”
AHN and Highmark are collaborating with Cedar in distinct but integrated ways. Patients who visit AHN providers and facilities will experience the new and enhanced billing, statement and call center process, and simplified access to flexible payment options, all driven by the Cedar Pay platform. For AHN patients who are also enrolled as Highmark members, the enhancements multiply. Beginning at the end of October, the nearly 300,000 members visiting AHN providers will now have the added benefit of having their insurance information incorporated directly into a single billing statement. Members will see how their benefits have been applied, available health spending account funds and their progress towards their deductible and out-of-pocket limits — both when paying AHN bills online, and on the mailed paper statements.
“We’re excited to be launching with healthcare industry leaders Highmark Health and Allegheny Health Network to solve this persistent problem,” added Cohen, Cedar’s president. “But this is only the beginning: Cedar is continuing to explore more ways of leveraging payer data and new integrations to enrich the end-to-end healthcare experience for today’s consumers.”
About Cedar
Cedar is committed to improving the healthcare financial experience for all. With an innovative platform that connects providers and payers, Cedar empowers healthcare consumers with an optimized journey — all powered by data science and interactive design. For Cedar clients, this leads to increased payments, more efficient operations and greater consumer loyalty. To learn more about why leading U.S. healthcare organizations trust Cedar to manage the end-to-end consumer experience from pre-registration to post-visit billing, visit www.cedar.com and join us on LinkedIn, Twitter, Facebook and YouTube.
About Highmark Health
Highmark Health, a Pittsburgh, Pennsylvania-based enterprise that employs more than 37,000 people who serve millions of Americans across the country, is the parent company of Highmark Inc., Allegheny Health Network, enGen, Helion, and Lumevity. Highmark Inc. and its subsidiaries and affiliates provide health insurance to more than six million members in Pennsylvania, West Virginia, Delaware, and New York, as well as dental insurance, and related health products through a national network of diversified businesses. Allegheny Health Network is an integrated delivery network in western Pennsylvania comprised of 14 hospitals, more than 2,600 affiliated physicians, ambulatory surgery centers, an employed physician organization, home and community-based health services, a research institute, a group purchasing organization, and health and wellness pavilions. enGen is focused on meeting the information technology platform and other business needs of the Highmark Health enterprise as well as unaffiliated health insurance plans by providing proven business processes, expert knowledge, and integrated cloud-based platforms. Helion works with payers to cultivate high-performing networks while empowering providers to operate at their best. Lumevity helps companies transform in ways that drive direct financial benefits while improving quality and increasing employee engagement. To learn more, visit www.highmarkhealth.org.
About Allegheny Health Network
Allegheny Health Network (AHN.org), a Highmark Health company, is an integrated health care delivery system serving the greater Western Pennsylvania region. The network is composed of 14 hospitals, ambulatory surgery centers, Health + Wellness Pavilions, an employed physician organization, home- and community-based health services, a research institute, and a group purchasing organization. AHN provides patients with access to a complete spectrum of advanced medical services, including nationally recognized programs for primary and emergency care, cardiovascular disease, cancer care, orthopedic surgery, neurology and neurosurgery, women’s health, diabetes and more. AHN employs approximately 21,000 people, has more than 2,600 physicians on its medical staff, and serves as a clinical campus for Drexel University College of Medicine and the Lake Erie College of Osteopathic Medicine.
Contact Information:
Rachel Borowski
Highmark Health
Bill Toland
Allegheny Health Network
Jenny Fiegoli
Cedar
Press Release Service
by
Newswire.com
Original Source:
Cedar’s Integrated Payer-Provider Patient Billing Platform Introduced to Highmark Inc. and Allegheny Health Network Customers
After developing severe esophagitis and being prescribed life-long medications, Jimmy Minhas, a doctor and founder of GerdLi, researched and created the world’s first natural supplement to relieve heartburn and acid reflux.
SEATTLE – November 1, 2022 – (Newswire.com)
Physician-engineered GerdLi is the natural answer for people who live with acid reflux and heartburn. It’s a premium-formulated antacid that maintains gut health and allows one to get back to eating the foods one loves. For those who hate to swallow pills, GerdLi comes as a small, easy-to-swallow capsule.
People that suffer from gastroesophageal reflux disease (GERD) are left to take prescription medications and must reduce or eliminate eating spicy foods, acrid vegetables, fatty, fried foods, fruit juices, wine, coffee and soda. Even large meals or eating before bedtime can cause uncomfortable acid reflux symptoms and, at times, damage to the esophagus.
GerdLi contains D-limonene, derived from the rinds of citrus fruits such as oranges, mandarins, lemons, limes and grapefruits and works in several ways to help with GERD.
“So many products on the market aiming to combat GERD and acid reflux, but GerdLi is by far the best remedy I’ve used. GerdLi offers great relief and the fact that it’s created by doctors makes it stand out even more.” MK, Happy Customer
GerdLi was developed over three years, and after three months of trials and testing, half the participants found improvement in their GERD symptoms. GerdLi may work as soon as one week and averages 2-4 weeks for relief of acid reflux symptoms. One study showed 72% of the participants experienced improvement within the 2-4 week period.
Although GerdLi is proven to alleviate heartburn and symptoms of GERD, lifestyle changes are just as crucial to a successful acid reflux regimen. GerdLi is meant to complement healthy lifestyle habits allowing patients to choose a natural way to relieve acid reflux and heartburn. Improved health includes staying active, eating clean foods and staying hydrated by drinking lots of water throughout the day.
GerdLi is manufactured in a special FDA-registered facility, ensuring it’s a safe supplement made with the highest quality ingredients. High-potency D-limonene is carefully sourced to be sure each bottle of GerdLi delivers the most effective results for reducing acid reflux. It works as an alkaline in the stomach to reduce acid, and its name is derived from lemon rinds, which have the highest concentration of limonene.
Once D-limonene is taken, it’s rapidly absorbed in the gastrointestinal tract and distributed into tissue. GerdLi reduces heartburn and reflux symptoms and may help some people reduce the amount of prescription medication they take.
The mission at GerdLi is to help people suffering from acid reflux while offering them an alternative to prescription medications that often cause side effects. GerdLi also cares about creating a healthier world, donating part of its proceeds to support the Esophageal Cancer Society.
Contact Information:
Matt Kane
Media manager
680 850 3345
Press Release Service
by
Newswire.com
Original Source:
GerdLi: New Supplement for Heartburn Was Made by a Physician Who Sought Natural Heartburn Relief
Additional capabilities help offer higher quality, increased efficiency and more accessible, satisfying healthcare
TORONTO …
Leading podiatrist in Wayne, New Jersey, partners with the Ankle & Foot Centers of America, the nation’s leading group of foot and ankle surgeons. This relationship allows doctors to dedicate their time to treating patients instead of administrating a podiatry practice.
WAYNE, N.J. – November 1, 2022 – (Newswire.com)
Renown New Jersey podiatrist Lindsey Calligaro, DPM, of Wayne Foot & Ankle Center has recently teamed with Ankle & Foot Centers of America, the market leader in physician practice management and process improvement, to better serve patients. Wayne Foot & Ankle Center has been providing the highest-quality care to patients for over 40 years, and is dedicated to improving the lives of people in the northern NJ community.
Dr. Lindsey Calligaro earned her Doctor of Podiatric Medicine from the New York College of Podiatric Medicine in 2011 and attended a comprehensive three (3) year residency in Scranton, Pennsylvania with Dr. Guido LaPorta. Dr. Calligaro served as Chief Fellow during her fellowship in Baltimore, Maryland, at the Rubin Institute for Advanced Orthopedics/International Center for Limb Lengthening. Dr. Calligaro’s training specialized in complex foot and ankle deformity correction and pediatric deformity correction. Dr. Calligaro treats a variety of foot and ankle problems, including bunions, heel pain, trauma, and flatfeet. She also specializes in all aspects of pediatric foot and ankle deformity correction with a special interest in clubfoot. Helping to serve the needs of patients is what brought Dr. Calligaro to podiatry, and it is what motivates her to provide the best care possible every day.
Teaming with Ankle & Foot Centers of America allows physicians like Dr. Calligaro to do what they do best, take care of patients. With Ankle and Foot Centers of America, Dr. Calligaro is now able to benefit from the most advanced software, reporting, and office support in the industry. As healthcare becomes more complicated with technology and regulation, physicians must rely on expert support.
Incorporating the central scheduling team and call center from Ankle and Foot Centers of America allows patients to make appointments with greater ease with this Wayne, NJ, Podiatrist. Whether booking online or over the phone, patients can now expect to have a more streamlined experience. Additionally, Ankle and Foot Centers of America incorporates advanced network safeguards to better protect patient data and provides new training for staff on the latest advances and changes in healthcare.
With a shared commitment to excellence and dedication to patient well-being, Dr. Calligaro and the team at Ankle and Foot Centers of America look forward to treating the foot and ankle needs of patients in north New Jersey.
About Ankle & Foot Centers of America – Founded in Atlanta over 30 years ago, Ankle & Foot Centers of America is dedicated to providing patients with top-tier service and support through best-in-class technology and processes so that physicians can optimize patient outcomes and satisfaction.
Contact Information:
Alexis Pickford
Marketing Representative
678-561-9000
Press Release Service
by
Newswire.com
Original Source:
New Jersey Podiatrist Teams with Ankle & Foot Centers of America
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.
LAS VEGAS – November 1, 2022 – (Newswire.com)
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. Finding Cannabis compounds with anti-inflammatory properties may be useful in decreasing inflammation associated with a wide range of serious human disorders, and these Cannabis compounds potentially have more favorable side effect profiles than NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which currently lead the anti-inflammatory market based on sales. Largely because of the increasing prevalence of chronic and auto-immune inflammatory disorders, the market for anti-inflammatory therapies is expected to grow to $191.42 billion by 2027.
“We believe that this is the first demonstration of the anti-inflammatory potential of some very potent minor cannabinoids and terpenes derived from Cannabis,” said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. “The identification of cell type-specific immune modulating effects by different individual cannabinoids and terpenes was an important first step in designing our novel anti-inflammatory therapies. The results from our second study on the anti-inflammatory effects of proprietary mixtures of these ingredients will be published subsequently with our collaborators at Michigan State University and Chaminade University.”
Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies. To determine whether these cannabinoids and terpenes could reduce inflammation, Gb Sciences’ colleagues at Michigan State University tested the individual Cannabis constituents over a wide range of concentrations in human, primary immune cells in a co-culture system that mimics the complex interactions that regulate the human immune system. Three immune cell types were chosen as representatives within these native human immune cell mixtures based on their important roles in modulating the inflammatory cascade.
This study demonstrated that delta-9 tetrahydrocannabinol (THC) had the greatest effect on reducing inflammatory biomarkers and processes in all three immune cell types. Following THC, the greatest immune activity modulation was measured by cannabidivarin (CBDV), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and lastly, cannabidiol (CBD) in decreasing order based on the number of statistically significant changes measured in inflammatory bioassays relative to the control. Some of these minor cannabinoids and the terpenes tested had very ‘selective’ anti-inflammatory effects, which targeted a single cell type and/or caused a change in only a single inflammatory bioassay.
This study entitled “Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes” was co-authored by Gb Sciences’ own President and Chief Science Officer, Andrea Small-Howard, and her collaborators Lance K. Blevins, Anthony P. Bach, Robert B. Crawford, Jiajun Zhou, Joseph E. Henriquez, Michael D. Rizzo, Sera Sermet, D.M. Isha Olive Khan, and Norbert Kaminski from Michigan State University (East Lansing, Michigan, USA) and Helen Turner from Chaminade University of Honolulu (Honolulu, Hawai’i, USA). The second part of this study measured the effects of proprietary mixtures of cannabinoids and terpenes on inflammation within this human, primary immune cell model, and this second study will be published next in collaboration with our colleagues at Michigan State University and Chaminade University.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Contact Information:
Madeleine Moench
Press Release Service
by
Newswire.com
Original Source:
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
